chlorpropamide has been researched along with naloxone in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (42.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Leslie, RD; Pyke, DA; Stubbs, WA | 1 |
| Ehrenreich, H; Goebel, FD | 1 |
| Baraniuk, JN; Mabbee, WG; Murray, RB | 1 |
| Alberti, KG; Barnett, AH; Eff, C; Leslie, RD; Pyke, DA; Spiliopoulos, AJ; Stubbs, WA | 1 |
| Alberti, KG; Barnett, AH; Burrin, J; Pyke, DA; Spiliopoulos, AJ; Stubbs, WA | 1 |
| Bowcock, S; Cooke, ED; Johnston, C; Medbak, S; Pyke, DA; Rees, LH; Wiles, PG | 1 |
| Heber, D; Mason, JS | 1 |
| Bellamy, D; Leslie, RD; Pyke, DA | 1 |
2 review(s) available for chlorpropamide and naloxone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The role of opioids in the endocrine function of the pancreas.
Topics: Animals; beta-Endorphin; Biomechanical Phenomena; Chlorpropamide; Dogs; Eating; Endocrine Glands; Endorphins; Enkephalins; Ethanol; Flushing; Guinea Pigs; Humans; Islets of Langerhans; Male; Morphine; Naloxone; Pancreas; Pancreatic Hormones; Peptides; Protein Precursors; Rats; Sheep | 1986 |
2 trial(s) available for chlorpropamide and naloxone
| Article | Year |
|---|---|
Naloxone, ethanol, and the chlorpropamide alcohol flush.
Topics: Adult; Alcoholic Intoxication; Chlorpropamide; Double-Blind Method; Ethanol; Flushing; Humans; Male; Motor Skills; Naloxone | 1987 |
Opiate receptors and the metabolic response to intravenous glucose.
Topics: Alanine; Blood Glucose; Chlorpropamide; Ethanol; Glucagon; Glucose; Humans; Insulin; Kinetics; Lactates; Lactic Acid; Naloxone; Pyruvates; Pyruvic Acid; Receptors, Opioid | 1982 |
15 other study(ies) available for chlorpropamide and naloxone
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Sensitivity to enkephalin as a cause of non-insulin dependent diabetes.
Topics: Alcoholic Beverages; Chlorpropamide; Diabetes Mellitus; Drug Antagonism; Endorphins; Enkephalins; Face; Hormones; Humans; Hypersensitivity; Naloxone; Skin Temperature | 1979 |
Metabolic studies in chlorpropamide-alcohol flush positive and negative Type 2 (non-insulin dependent) diabetic patients with and without retinopathy.
Topics: Aged; Blood Glucose; Chlorpropamide; Diabetes Mellitus; Diabetic Retinopathy; Drug Interactions; Ethanol; Face; Female; Glucose Tolerance Test; Glycerol; Humans; Insulin; Male; Middle Aged; Naloxone; Triglycerides | 1983 |
The role of endogenous opioids in the chlorpropamide alcohol flush.
Topics: Administration, Oral; Adult; Aged; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Interactions; Enkephalin, Methionine; Ethanol; Female; Flushing; Humans; Indomethacin; Injections, Intravenous; Male; Middle Aged; Naloxone | 1984 |
Endogenous opiates modulate insulin secretion in flushing noninsulin-dependent diabetics.
Topics: Adult; Blood Glucose; Blushing; Chlorpropamide; Diabetes Mellitus; Drug Interactions; Ethanol; Glucose Tolerance Test; Humans; Insulin; Middle Aged; Naloxone | 1982 |
Asthma induced by enkephalin.
Topics: Asthma; Chlorpropamide; Drug Synergism; Enkephalins; Ethanol; Forced Expiratory Volume; Humans; Male; Middle Aged; Naloxone | 1980 |